The Federal Reserve has held interest rates at its March FOMC meeting, bookended by a press conference where Fed Chair Jerome Powell commented on the central bank's efforts to navigate economic ...

Prefer Newsweek on Google to see more of our trusted coverage when you search. It doesn’t happen often. At the 2011 National Prayer Breakfast in Washington, the keynote speaker wasn’t a pastor, ...

Oscar-winning director and Hollywood actor Mel Gibson will return to Glasgow for a black-tie event to celebrate 30 years of William Wallace epic Braveheart. Did you know with a Digital Subscription to ...

We all know that historical movies can be inaccurate. Sometimes, they get historical figures completely wrong – for example, Pocahontas was a child when she met John Smith, and so was Isabella of ...

In a chilling social media video that is beyond irony, clips from Braveheart, Gladiator, Superman and Top Gun are crassly interspersed with real kill-shot footage of the attacks in Iran White House ...

NEW DELHI: Tyson, a four-legged Army hero, was shot in the leg during Operation Trashi-I in Kishtwar, Jammu and Kashmir, and is “recovering well.” The Army on Tuesday said he is “wounded but in high ...

Braveheart Bio is a clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions. The company is backed by experienced life science ...

The bedroom in which Mel Gibson stayed during the filming of Braveheart. Photo: Niall Mullen A rallying cry has gone out to Braveheart fans who fancy getting their hands on some unique items used by ...

Bristol Myers Squibb currently has the only drug approved specifically for treating obstructive hypertrophic cardiomyopathy, a debilitating disorder that can progress to heart failure. But safety ...

NEW YORK CITY – Curtis Sliwa says he’s charging into the final stretch of New York City’s mayoral race like "Braveheart" — confident, defiant and ready to die on his sword for the city he loves. In an ...

Braveheart Bio has waded into the fight for a heart disease market, paying (PDF) $65 million upfront for a rival to Bristol Myers Squibb’s Camzyos and Cytokinetics’ aficamten. Jiangsu Hengrui ...